Premium
The value of γ‐seminoprotein in combination with prostate specific antigen in detecting prostate cancer
Author(s) -
Nakashima Jun,
Nagata Hirohiko,
Sumitomo Makoto,
Miyajima Akira,
Tachibana Masaaki,
Baba Shiro,
Jitsukawa Seido,
Murai Masaru
Publication year - 1999
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1046/j.1442-2042.1999.00063.x
Subject(s) - medicine , prostate cancer , urology , prostate , prostate specific antigen , receiver operating characteristic , cancer , pca3 , oncology , gynecology
Background : The present study was undertaken to investigate the value of gamma‐seminoprotein (γ‐Sm) and the γ‐Sm/prostate specific antigen (PSA) ratio in combination with serum PSA in detecting prostate cancer. Methods : Prostate specific antigen, γ‐Sm and the γ‐Sm/PSA ratio were evaluated in 112 patients with untreated prostate cancer and 90 patients without prostate cancer who had serum PSA and γ‐Sm levels above their respective detection limits. Results: When data for all of the patients were analyzed, serum PSA and γ‐Sm levels were significantly higher and the γ‐Sm/PSA ratio was significantly lower in patients with prostate cancer than patients without prostate cancer. The serum PSA and γ‐Sm levels significantly increased and the γ‐Sm/PSA ratio significantly decreased with advancing clinical stage in patients with prostate cancer. Among the patients with serum PSA levels ranging from 1.8 to 6 ng/mL, the γ‐Sm/PSA ratio was significantly lower (P < 0.05) and γ‐Sm levels were lower (P = 0.054) in the patients with prostate cancer than in those without prostate cancer, but serum PSA levels were not significantly different (P = 0.53). A receiver operating characteristic (ROC) analysis demonstrated that the areas under the ROC curves were 0.54 for PSA, 0.65 for γ‐Sm and 0.69 for the γ‐Sm/PSA ratio for prediction of prostate cancer in the PSA range from 1.8 to 6 ng/mL, although the ROC analysis suggested that the γ‐Sm/PSA ratio does not provide significant advantage over PSA in detecting prostate cancer when all of the patients were analyzed. Conclusions : These results suggest that the γ‐Sm/PSA ratio and γ‐Sm may facilitate differentiation between patients with and without prostate cancer who have intermediate PSA levels.